Woodline Partners’s Aurinia Pharmaceuticals AUPH Stock Holding History

Woodline Partners’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.74M	Hold	456,259	–	–	0.02%	591
2026 Q1	$6.76M	Hold	456,259	–	–	0.03%	601
2025 Q4	$7.28M	Hold	456,259	–	–	0.03%	542
2025 Q3	$5.04M	Sell	456,259 -44,157	-9%	-$482K	0.02%	566
2025 Q2	$4.24M	Hold	500,416	–	–	0.02%	594
2025 Q1	$4.02M	Sell	500,416 -349,061	-41%	-$2.83M	0.03%	556
2024 Q4	$7.63M	Buy	849,477 +348,983	+70%	+$2.85M	0.05%	406
2024 Q3	$3.67M	Sell	500,494 -113,572	-18%	-$704K	0.03%	427
2024 Q2	$3.51M	Buy	614,066 +113,511	+23%	+$598K	0.03%	373
2024 Q1	$2.51M	Sell	500,555 -144,639	-22%	-$981K	0.02%	415
2023 Q4	$5.8M	Buy	645,194 +145,194	+29%	+$1.2M	0.06%	299
2023 Q3	$3.88M	Hold	500,000	–	–	0.05%	339
2023 Q2	$4.84M	Sell	500,000 -453,462	-48%	-$4.71M	0.06%	299
2023 Q1	$10.4M	Sell	953,462 -271,991	-22%	-$2.4M	0.14%	193
2022 Q4	$5.29M	Buy	+1,225,453	New	+$7.11M	0.07%	305
2022 Q3	–	Sell	-169,209	Closed	-$1.7M	–	753
2022 Q2	$1.7M	Buy	+169,209	New	+$1.89M	0.03%	455

Other funds holding AUPH

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Woodline Partners's AUPH Position: Q2 2026 in Review

Woodline Partners held its Aurinia Pharmaceuticals (AUPH) position steady in Q2 2026 at 456,259 shares worth $7.74M. The position accounts for 0.02% of the portfolio, ranked #591.

Woodline Partners first reported a position in AUPH in Q2 2022 and has held it in 16 quarters since. The position peaked at $10.4M in Q1 2023. 282 funds tracked by Wall St. Rank hold AUPH as of Q2 2026.

Woodline Partners held 456,259 shares of Aurinia Pharmaceuticals worth $7.74M as of Q2 2026.
Woodline Partners left its Aurinia Pharmaceuticals share count unchanged in Q2 2026.
Aurinia Pharmaceuticals made up 0.02% of Woodline Partners's portfolio in Q2 2026, its #591 holding.
Woodline Partners first reported a position in Aurinia Pharmaceuticals in Q2 2022 and has held it in 16 quarters since.
Woodline Partners's Aurinia Pharmaceuticals position peaked at $10.4M in Q1 2023.
282 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2026.

Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.